Clinical Report: Closing the Gap in Continuous Glucose Monitoring
Overview
The proposed three-stage model for type 2 diabetes emphasizes the importance of continuous glucose monitoring (CGM) metrics, particularly time in tight range (TITR), in managing glycaemic variability. However, actionable algorithms to translate CGM data into therapeutic strategies are currently lacking, highlighting a significant gap in clinical practice.
Background
Effective management of type 2 diabetes is crucial due to its rising prevalence and associated complications, including cardiovascular disease. The introduction of a three-stage model based on β-cell function and glycaemic trajectory aims to enhance early detection and intervention. Continuous glucose monitoring (CGM) has emerged as a vital tool in this context, yet its full potential is hindered by the absence of structured frameworks for translating CGM data into clinical action.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
The three-stage model for type 2 diabetes focuses on β-cell trajectory and CGM metrics.
Time in tight range (TITR) is proposed as a critical metric for assessing glycaemic control.
Barriers to effective CGM utilization include metric overload and clinical inertia prioritizing hypoglycaemia avoidance.
A three-step closed-loop clinical model is suggested to improve CGM interpretation and therapeutic responses.
Provisional TITR thresholds are established for each disease stage, emphasizing the need for sustainable glycaemic stability.
Clinical Implications
Healthcare professionals should consider the new three-stage model for type 2 diabetes in their practice to enhance early intervention strategies. The integration of CGM metrics into clinical decision-making can improve glycaemic control and potentially reduce cardiovascular risks associated with glycaemic variability.
Conclusion
The advancement of CGM metrics in diabetes management underscores the need for actionable clinical frameworks. Addressing the identified barriers will be essential for optimizing patient outcomes in diabetes care.
